argenx SE vs Eli Lilly & Co.
ARGX vs LLY — side-by-side comparison from reported financials. ARGX leads 5, LLY leads 6 of 11 comparable metrics.
argenx SE
ARGX · Healthcare
$825.03+0.78%Strong
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | ARGX | LLY |
|---|---|---|
| Price | $825.03 | $1 177.20 |
| Market cap | $51.9B | $1.05T |
| Revenue (TTM) | $4.24B | $79.7B |
| Revenue growth | +116.2% | +31.7% |
| Net margin | 30.5% | 33.5% |
| Free cash flow | $970M | $18.2B |
| Net cash (debt) | $5.14B | ($35.2B) |
| 1-year price return | +2.5% | +37.6% |
| P/E | 20.1 | 41.6 |
| P/E vs own history (cheap-side %) | 92% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 22% | 93% |
| Altman Z-score | 21.86 | 7.10 |
| CV checks passed | 8 of 10 | 11 of 10 |
| Employees | 1,863 | 50,000 |
Full résumé-style profiles: ARGX CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.